SynthesisFrontiers in oncology2026
Prognostic value of systemic inflammatory response index in patients with bladder cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The systemic inflammatory response index (SIRI) has been confirmed to be associated with the prognosis of various solid tumors. The predictive value of the preoperative SIRI on the prognosis of bladder cancer (BC) patients remains unknown. This systematic review and meta-analysis investigated the association between preoperative SIRI and the prognosis of BC patients. Methods: Relevant studies were retrieved from PubMed, Web of Science, Embase, the Cochrane Library, Chinese National Knowledge Infrastructure, Wan Fang database, and VIP Chinese Science and Technology Periodicals Database from inception to April 18, 2026. The prognostic value of preoperative SIRI for BC patients was assessed using pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Subgroup analyses were performed to investigate potential sources of heterogeneity, and sensitivity analyses were conducted to assess the robustness of the findings. Results: Fourteen studies comprising 4,098 patients were included. An elevated SIRI was significantly associated with poorer overall survival (OS; HR = 2.20, 95% CI = 1.61-3.01), recurrence-free survival (RFS; HR = 2.13, 95% CI = 1.74-2.61), and progression-free survival (PFS; HR = 4.06, 95% CI = 2.67-6.15) in BC patients. Conclusion: SIRI is a predictor of the survival, recurrence and disease progression in BC patients. Further large-scale prospective studies are required to confirm these findings. Systematic review registration: https://inplasy.com/inplasy-2026-5-0016/, identifier 202650016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.